SCHEDULE 13G: Commodore Capital Discloses 5% Stake in Celldex Therapeutics
Beneficial Ownership Disclosure
Commodore Capital LP and Commodore Capital Master LP have jointly disclosed a 5.0% beneficial ownership stake in Celldex Therapeutics, Inc. common stock.
Summary
- Commodore Capital LP, a Delaware limited partnership, and Commodore Capital Master LP, a Cayman Islands exempted limited partnership, have filed a Schedule 13G.
- The filing discloses that Commodore Capital LP and Commodore Capital Master LP collectively beneficially own 3,350,000 shares of common stock of Celldex Therapeutics, Inc.
- This ownership represents 5.0% of Celldex Therapeutics, Inc.'s outstanding common stock.
- The ownership percentage is based on 66,383,811 shares of common stock reported as issued and outstanding by Celldex Therapeutics, Inc. as of February 14, 2025.
- Commodore Capital LP acts as the investment manager to Commodore Capital Master LP.
- Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
- The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment.
Sentiment
Score: 5
Explanation: A routine regulatory filing disclosing a passive ownership stake, with no direct positive or negative implications for the issuer's operational or financial performance detailed within the document itself.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 2025-02-14 | Date as of which Celldex Therapeutics, Inc. reported 66,383,811 shares of Common Stock issued and outstanding in its Form 10-K. |
| 2025-02-27 | Date Celldex Therapeutics, Inc. filed its Annual Report on Form 10-K with the SEC. |
| 2025-04-03 | Date of event which requires filing of this statement (acquisition of 5% stake). |
| 2025-04-10 | Date the Schedule 13G statement was signed by Michael Kramarz for Commodore Capital LP and Commodore Capital Master LP. |
Keywords
Celldex Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.